Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Idelalisib Impairs TREM-1 and TLR Mediated Neutrophil Activation

Astrid Hasibeder, Nicole Stadler, Pamela Aranda Lopez, Alexander Desuki, Oliver Kriege, Alexander N.R. Weber, Christian Michel, Daniel Teschner, Georg Hess, MD, Matthias Theobald, MD, Markus Radsak, MD

Blood (2016) 128 (22): 2510.

https://doi.org/10.1182/blood.V128.22.2510.2510

Published: 2016

Journal Articles

Design and Development of a Novel Orally-Active, PI3K-p110Beta/Delta Inhibitor with Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity

Stephen Joseph Shuttleworth, PhD

Blood (2015) 126 (23): 2052.

https://doi.org/10.1182/blood.V126.23.2052.2052

Published: 2015

Journal Articles

Phosphoinositide 3'-Kinase (PI3K) Delta Inhibitor, GS-9820, Enhances Anti-Tumor Efficacy When Combined with Conventional Chemotherapeutic Agents in Primary Samples and Human Tumor Xenograft Model of Multiple Myeloma

Eric Sanchez, Mingjie Li, Cathy Wang, Haiming Chen, MD., Ph.D, Dave M. Johnson, Brian J. Lannutti, PhD, James R. Berenson, MD

Blood (2012) 120 (21): 4017.

https://doi.org/10.1182/blood.V120.21.4017.4017

Published: 2012

Journal Articles

Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemias and High Risk Myelodysplastic Syndromes (MDS)

Kelly J. Norsworthy, MD, Alexander E Perl, MD, Martin Carroll, MD, Selina M. Luger, MD, Kenneth S. Bauer, PharmD, PhD, Michael L. Tidwell, CRNP, Dina Ioffe, BA, Maria R. Baer, MD, Edward A. Sausville, MD, PhD, Ivana Gojo, MD

Blood (2011) 118 (21): 1557.

https://doi.org/10.1182/blood.V118.21.1557.1557

Published: 2011

Journal Articles

CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma

Sarah A Meadows, BS, Adam Kashishian, BS, Dave Johnson, Volker Diehl, Brian Lannutti, PhD

Blood (2010) 116 (21): 3926.

https://doi.org/10.1182/blood.V116.21.3926.3926

Published: 2010

Journal Articles

Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma.

Craig C Hofmeister, M.D., Don Benson, MD, PhD, Yvonne A Efebera, M.D., Sherif Farag, MBBS, PhD, Michael R. Grever

Blood (2009) 114 (22): 2884.

https://doi.org/10.1182/blood.V114.22.2884.2884

Published: 2009

Journal Articles

CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM)

Hiroshi Ikeda, MD, PhD, Teru Hideshima, MD, PhD, Yutaka Okawa, MD, PhD, Sonia Vallet, MD, Samantha Pozzi, Loredana Santo, MD, Gullu Gorgun, Mariateresa Fulciniti, Noopur S. Raje, MD, Giulia Perrone, Nikhil Munshi, MD, Paul Richardson, MD, Brian J Lannutti, Kamal D. Puri, Neill A. Giese, Kenneth C. Anderson, MD

Blood (2008) 112 (11): 2753.

https://doi.org/10.1182/blood.V112.11.2753.2753

Published: 2008

Journal Articles

PI-103, a Dual Inhibitor of Class I Phosphatidylinositide 3-Kinase and mTOR, Has Anti-Leukemic Activity in Acute Myeloid Leukemia.

Sophie Park, MD, Nicolas Chapuis, MD, Valerie Bardet, PhD, Lise Willems, MD, Jerome Tamburini, MD, Zachary A. Knight, PhD, Kevan M. Shokat, PhD, Nabih Azar, MD, Norbert Ifrah, MD, PhD, Francois Dreyfus, MD, PhD, Patrick Mayeux, MD, Catherine Lacombe, MD, PhD, Didier Bouscary, MD, PhD

Blood (2007) 110 (11): 876.

https://doi.org/10.1182/blood.V110.11.876.876

Published: 2007

Journal Articles

Phosphatidylinositide 3-kinase localizes to cytoplasmic lipid bodies in human polymorphonuclear leukocytes and other myeloid-derived cells

Wengui Yu, Jessica Cassara, Peter F. Weller

Blood (2000) 95 (3): 1078–1085.

https://doi.org/10.1182/blood.V95.3.1078.003k16_1078_1085

Published: 2000

NARROW

Idelalisib Impairs TREM-1 and TLR Mediated Neutrophil Activation

Design and Development of a Novel Orally-Active, PI3K-p110Beta/Delta Inhibitor with Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity

Phosphoinositide 3'-Kinase (PI3K) Delta Inhibitor, GS-9820, Enhances Anti-Tumor Efficacy When Combined with Conventional Chemotherapeutic Agents in Primary Samples and Human Tumor Xenograft Model of Multiple Myeloma

Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemias and High Risk Myelodysplastic Syndromes (MDS)

CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma

Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma.

CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM)

PI-103, a Dual Inhibitor of Class I Phosphatidylinositide 3-Kinase and mTOR, Has Anti-Leukemic Activity in Acute Myeloid Leukemia.

Phosphatidylinositide 3-kinase localizes to cytoplasmic lipid bodies in human polymorphonuclear leukocytes and other myeloid-derived cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only